Mincai li | vascular calcification | Best Researcher Award

Published on by Cardiology and Cardiovascular Medicine

Prof. Dr. Mincai li | vascular calcification | Best Researcher Award 

Prof. Dr. Mincai li, Hubei University of Science and Technology, China

Prof. Dr. Mincai Li is a distinguished academic at Hubei University of Science and Technology, China. He holds an MD and Master’s degree in Pathology and Pathophysiology from Huazhong University of Science and Technology. With extensive experience in teaching, Prof. Li has served as a Professor since 2017, after roles as Associate Professor and Lecturer at the same institution. His research focuses on the molecular mechanisms of atherosclerosis and the efficacy of glioma drugs. He has published over 40 scientific papers, including 15 SCI-indexed articles, and has received multiple awards for his scientific and teaching contributions.

Author Profile

Scopus Profile

🎓 Education Background:

Prof. Dr. Mincai Li completed his MD in Pathology and Pathophysiology at Huazhong University of Science and Technology (2007-2010), graduating in the top 10% of his class. He also earned his Master’s in Pathology and Pathophysiology from the same institution (2004-2007), ranking in the top 10%. Prior to that, he obtained a Bachelor’s in Clinical Medicine from Hubei University of Science and Technology (1993-1998), where he was in the top 30% of his cohort.

💼 Professional Experience:

Prof. Dr. Mincai Li has an extensive academic career at Hubei University of Science and Technology, where he has held progressively senior roles. Since January 2017, he has served as a Professor, following his tenure as Associate Professor from January 2012 to December 2016. From July 2010 to December 2011, he was a Lecturer, and earlier in his career, he worked as a Teaching Assistant from July 1998 to August 2004. Throughout his tenure, Prof. Dr. Li has contributed significantly to education and research in his field, shaping the academic environment at the university.

🩺 Medical Education & Teaching:

Prof. Dr. Mincai Li has made significant contributions to medical education, primarily teaching Pathology and Oral Histopathology courses. He has played a leading role in three provincial teaching research projects within Hubei’s higher education institutions, demonstrating his commitment to advancing academic standards. His exceptional teaching efforts have been recognized with awards, including a second prize and a third prize for teaching achievements at Hubei University of Science and Technology. Prof. Dr. Li’s dedication to both education and research has made a lasting impact on the academic community and the development of future medical professionals.

🔬 Scientific Research:

Prof. Dr. Mincai Li’s research primarily focuses on the molecular mechanisms of atherosclerosis and the efficacy of glioma drugs. He has led and contributed to 10 national, provincial, and municipal research projects, showcasing his expertise in these critical areas. Prof. Li has published over 40 scientific papers, including 15 SCI-indexed articles, and has edited a textbook. His significant contributions to scientific research have earned him recognition, including a second prize and a third prize for scientific and technological progress in Xianning City. His work continues to advance the understanding of critical medical conditions and therapeutic approaches.

🏅 Achievements and Honors:

Prof. Dr. Mincai Li has earned several prestigious awards throughout his career. In 2015, he was honored with the Second and Third Prizes for Science and Technology Progress in Xianning City, recognizing his contributions to scientific advancement. In 2016, he received both the Second and Third Prizes for Teaching Achievements at Hubei Institute of Science and Technology, highlighting his dedication to education. That same year, Prof. Li was awarded the Third Prize for the Second Natural Science Outstanding Academic Achievement Thesis Award in Xianning City, further acknowledging his impactful research and academic excellence. These accolades reflect his commitment to both teaching and scientific progress.

🌟Conclusion:

Prof. Dr. Mincai Li is a highly accomplished academic and researcher at Hubei University of Science and Technology, China. With a strong background in Pathology and Pathophysiology, he has made significant contributions to both education and scientific research. His work on atherosclerosis and glioma drugs has earned him national and regional recognition. As a dedicated professor, he has shaped the academic development of many students, while his research continues to advance medical science. Prof. Li’s numerous awards and honors reflect his unwavering commitment to excellence in both teaching and research.

Top Notable Publications:

Target analysis and identification of curcumin against vascular calcification

Authors: Li, Q., Zhou, Q., Li, S., Li, M., Xia, H.

Journal: Scientific Reports

Year: 2024

The causal relationship between thoracic aortic aneurysm and immune cells: a mendelian randomization study

Authors: Liu, G., Pan, S., Xia, H., Li, M., Wu, A.

Journal: BMC Cardiovascular Disorders

Year: 2024

Attenuating Atherosclerosis through Inhibition of the NF-κB/NLRP3/IL-1β Pathway-Mediated Pyroptosis in Vascular Smooth Muscle Cells (VSMCs)

Authors: Li, S., Li, Q., Zhou, Q., Liu, C., Li, M.

Journal: Cardiovascular Therapeutics

Year: 2024

Identification of key genes and pathways in atherosclerosis using integrated bioinformatics analysis

Authors: Li, S., Li, Q., Zhou, Q., Liu, C., Li, M.

Journal: BMC Medical Genomics

Year: 2023

Bioinformatic Identification of the Pyroptosis-Related Transcription Factor-MicroRNA-Target Gene Regulatory Network in Angiotensin II-Induced Cardiac Remodeling and Validation of Key Components

Authors: Huang, T., Ding, J., Lin, L., Yu, L., Li, M.

Journal: Frontiers in Bioscience (Landmark edition)

Year: 2023

Increased Neuromedin B is Associated with a Favorable Prognosis in Glioblastoma

Authors: Li, S., Li, Q., Zhou, Q., Liu, C., Li, M.

Journal: Frontiers in Bioscience – Landmark

Year: 2023

Study on mechanism of resveratrol regulation of NLRP3 mediated pyroptosis of vascular smooth muscle cells resistance to atherosclerosis

Authors: Li, S., Li, Q., Zhou, C., Ouyang, C., Li, M.

Journal: Drug Evaluation Research

Year: 2022

Curcumin suppresses glioblastoma cell proliferation by p-AKT/mTOR pathway and increases the PTEN expression

Authors: Wang, Z., Liu, F., Liao, W., Li, M., Xia, H.

Journal: Archives of Biochemistry and Biophysics

Year: 2020

Captopril Attenuates the Upregulated Connexin 43 Expression in Artery Calcification

Authors: Li, M., Wang, Z., Shao, J., Yu, L., Hu, Z.

Journal: Archives of Medical Research

Year: 2020

Paweł Rajewski | Cardiovascular risk | Best Research Article Award | Best Research Article Award

Published on by Cardiology and Cardiovascular Medicine

🏥Current Position and Roles:

Dr. Paweł Rajewski is a distinguished medical doctor, professor, and the rector of the Faculty of Health Sciences at the University of Health Sciences in Bydgoszcz. He holds the vital role of Provincial Consultant in Infectious Diseases for the Kuyavian-Pomeranian Voivodeship, providing oversight and strategic insights on infectious disease management in the region. Dr. Rajewski serves as the Head of the Department of Internal Medicine and Infectious Diseases at the Tadeusz Browicz Provincial Infectious Disease Hospital in Bydgoszcz, as well as the Head of the Liver, Internal, Infectious, and Metabolic Disorders Clinic at CM Gizińscy in Bydgoszcz. Previously, he served as the Medical Director and Head of the Department of Internal Medicine and Hepatology at the Emil Warmiński Multispecialist City Hospital. Through these roles, he contributes to the health of countless patients while also shaping medical policy and practice.

🎓Academic Background:

Dr. Rajewski’s academic journey has been marked by an enduring commitment to medicine, specializing in areas such as internal medicine, infectious diseases, hepatology, and clinical transplantation. His qualifications in these areas form the bedrock of his clinical and academic expertise, enabling him to deliver high-impact research and patient care in fields that are central to public health. Dr. Rajewski’s education includes specialty certifications as a lipidologist, accredited by the Polish Lipid Association, and an obesitologist with certifications from the Polish Association for the Study of Obesity and the Polish Society for Obesity Treatment.

📚Research Interests and Publication Achievements: 

Dr. Rajewski has contributed over 200 articles, primarily focused on metabolic disorders, obesity, liver diseases, and cardiovascular risk factors. His work, published in reputed medical journals, has been instrumental in advancing knowledge on these critical health issues. His research sheds light on complex metabolic processes, influencing both preventive and therapeutic approaches to conditions like non-alcoholic fatty liver disease and atherosclerosis. His publications are widely recognized for their scientific rigor and relevance, contributing to his esteemed reputation in the medical research community.

🔬Ongoing Research Projects:

Dr. Rajewski is currently engaged in various research projects that address emerging concerns in metabolic health and infectious diseases. His work on liver disease mechanisms and cardiovascular risk factors associated with obesity and metabolic syndrome aims to uncover better diagnostic markers and treatment pathways. A recent focus involves studying COVID-19’s impact on liver function and the interplay between viral infections and metabolic health, topics highly relevant in today’s healthcare landscape.

👥Professional Associations and Certifications: 

Dr. Rajewski’s memberships in prestigious medical associations, including the Polish Lipid Association and the Polish Association for the Study of Obesity, underscore his dedication to staying at the forefront of medical science. His certified expertise as a lipidologist and obesitologist enables him to approach health issues with a comprehensive understanding of lipid and metabolic disorders, enhancing the efficacy of treatments and preventive measures.

🏆Scholarships and Awards: 

Dr. Rajewski’s contributions to medicine have earned him numerous accolades, recognizing his achievements in research and clinical practice. These awards celebrate his innovation in metabolic research and his pivotal role in infectious disease management. His scholarship funding reflects a legacy of excellence and a commitment to advancing medical science.

📖Training & Workshops Attended:

In his pursuit of continual growth, Dr. Rajewski has attended a series of specialized workshops on bioinformatics, advanced diagnostics, and clinical applications in infectious disease management. These workshops equip him with cutting-edge skills that he applies to his daily work, benefiting patients and enhancing the training of his medical students.

💻Contributions to Bioinformatics and Clinical Research: 

A proficient bioinformatician, Dr. Rajewski integrates data science and computational tools in his research on metabolic diseases and infectious pathogens. By utilizing bioinformatics, he has been able to analyze complex datasets, leading to insights into genetic predispositions and disease progression. His ability to harness bioinformatics tools strengthens his work in both metabolic and infectious disease studies, positioning him at the cutting edge of medical research.

🎤Oral Presentations and Conferences: 

As a frequent presenter at national and international conferences, Dr. Rajewski shares his research findings with the medical community. His presentations cover topics like liver disease pathogenesis, metabolic syndrome treatments, and emerging infectious diseases. He contributes actively to knowledge exchange, with his lectures serving as valuable learning resources for both peers and students.

📊Key Tasks and Responsibilities as a Researcher:

In his research role, Dr. Rajewski coordinates multi-disciplinary teams, designing studies, and conducting extensive data analyses. His responsibilities include overseeing clinical trials and ensuring the ethical integrity of research protocols. His dedication to stringent research standards has led to significant findings that improve patient care protocols and inform public health strategies.

🌠Success Factors:

Dr. Rajewski attributes his success to his commitment to continuous learning, innovation, and collaboration. His ability to bridge theoretical research with practical applications in healthcare makes his contributions exceptionally valuable. Additionally, his leadership in the clinical setting exemplifies his holistic approach to healthcare, balancing research with direct patient care.

🔍Publications & Laboratory Experience:

Dr. Rajewski’s extensive laboratory experience includes advanced diagnostics in liver diseases, where he employs innovative techniques to diagnose and manage conditions like hepatitis and liver fibrosis. His publications detail his findings on the effectiveness of new biomarkers, offering insights that enhance both diagnostics and treatment options for liver and metabolic disorders.

🌐Conclusion: 

Dr. Paweł Rajewski’s career exemplifies a dedication to excellence in medicine, research, and public health. His multifaceted expertise in internal medicine, infectious diseases, and metabolic health has propelled him to the forefront of healthcare in Poland. Dr. Rajewski’s contributions are invaluable to the fields of hepatology and infectious disease, positively impacting patient care and advancing medical knowledge. Through his foundation, research, and clinical roles, he continues to shape the future of health sciences, creating a lasting legacy of compassion, knowledge, and innovation.

 

Top Notable Publications:

 

Hepatitis C Infection Is Not a Cardiovascular Risk Factor in Young Adults

Authors: Not listed; need to check for full author details.

Year: 2024

Citation: Biomedicines, 2024, 12(10), article 2400. DOI: 10.3390/biomedicines12102400.

Feasibility and Cardiometabolic Effects of Time-Restricted Eating in Patients with Metabolic Syndrome

Authors: Not listed; need to check for full author details.

Year: 2024

Citation: Nutrients, 2024, 16(12), article 1802. DOI: 10.3390/nu16121802.

Hepatitis C Infection as a Risk Factor for Hypertension and Cardiovascular Diseases: An EpiTer Multicenter Study

Authors: Not listed; need to check for full author details.

Year: 2022

Citation: Journal of Clinical Medicine, 2022, 11(17), article 5193. DOI: 10.3390/jcm11175193.

The Dynamics of Changes in the Concentration of IgG against the S1 Subunit in Polish Healthcare Workers in the Period from 1 to 12 Months after Injection, Including Four COVID-19 Vaccines

Authors: Not listed; need to check for full author details.

Year: 2022

Citation: Vaccines, 2022, 10(4), article 506. DOI: 10.3390/vaccines10040506.

HCV Genotype Has No Influence on the Incidence of Diabetes—EpiTer Multicentre Study

Authors: Not listed; need to check for full author details.

Year: 2022

Citation: Journal of Clinical Medicine, 2022, 11(2), article 379. DOI: 10.3390/jcm11020379.

Anti-SARS-CoV-2 IgG against the S Protein: A Comparison of BNT162b2, mRNA-1273, ChAdOx1 nCoV-2019 and Ad26.COV2.S Vaccines

Authors: Not listed; need to check for full author details.

Year: 2022

Citation: Vaccines, 2022, 10(1), article 99. DOI: 10.3390/vaccines10010099.

Pilot Clinical Trial of Time-Restricted Eating in Patients with Metabolic Syndrome

Authors: Not listed; need to check for full author details.

Year: 2021

Citation: Nutrients, 2021, 13(2), article 346. DOI: 10.3390/nu13020346.

Resveratrol’s Impact on Vascular Smooth Muscle Cells Hyporeactivity: The Role of Rho-Kinase Inhibition

Authors: Not listed; need to check for full author details.

Year: 2020

Citation: BioMed Research International, 2020, article 9012071. DOI: 10.1155/2020/9012071.

Zakażenie wirusem cytomegalii w praktyce klinicznej – diagnostyka, objawy i leczenie w świetle aktualnej wiedzy

Authors: Not listed; need to check for full author details.

Year: 2019

Citation: Forum Zakażeń, 2019, issue 4, article FZ2019042. DOI: 10.15374/FZ2019042.

Melatonin Supplementation Lowers Oxidative Stress and Regulates Adipokines in Obese Patients on a Calorie‐Restricted Diet

Authors: Not listed; need to check for full author details.

Year: 2017

Citation: Oxidative Medicine and Cellular Longevity, 2017, article 8494107. DOI: 10.1155/2017/8494107.

Jihong Hu | Hypertension | Best Researcher Award 

Published on by Cardiology and Cardiovascular Medicine

🎓Current Position and Research Focus:

Dr. Hu holds a position at a respected institution where they continue to contribute significantly to the fields of preventive medicine and public health. Their ongoing research focuses on areas such as hypertension, cardiovascular risk assessment, and traditional Chinese medicine applications for chronic disease prevention. Through innovative studies and applied clinical work, Dr. Hu aims to enhance understanding of disease mechanisms and contribute to the development of preventive strategies in both Western and traditional Chinese medicine.

📚Academic Background:

Dr. Hu began their academic journey at Ningxia Medical University, earning a master’s degree in preventive medicine in 2000. Subsequently, they completed an undergraduate degree in the same field, graduating in 2003. Driven by a passion for epidemiology and health statistics, Dr. Hu went on to earn a doctorate from Peking Union Medical College in 2007. These degrees laid a solid foundation for a career devoted to advancing preventive medicine in both academic and clinical settings.

📝Publications and Scientific Achievements:

Over the last five years, Dr. Hu has contributed numerous papers to prestigious journals, often as the first author or corresponding author. Notable publications include research on:

  • Salt sensitivity and hypertension, investigating how salt substitutes impact blood pressure across different age groups.
  • PD-L1 expression in colorectal cancer, where Dr. Hu’s analysis provided insights into prognostic factors.
  • Gut microbiome research, exploring its association with diseases like obesity and hypertension.

These publications highlight Dr. Hu's versatility in addressing a wide range of health issues, often using meta-analyses to consolidate knowledge across studies.

🔬Ongoing Research Projects:

Dr. Hu actively participates in numerous research projects, often funded by prestigious bodies like the National Natural Science Foundation of China. Current projects include:

  • Internet+Chinese Medicine Integration: Investigating the role of Chinese medicine in preventing and controlling chronic diseases through technology.
  • Pediatric Intestinal Microecology: Examining how gut health affects respiratory infections in children.
  • Lumbar Disc Herniation Therapy: Standardizing Chinese medicine treatments for lumbar issues, focusing on Gansu’s regional medical practices.
  • Stroke and Traditional Medicine: Studying ischemic stroke through a traditional Chinese medicine perspective and assessing its diagnostic value.

These projects underscore Dr. Hu’s dedication to combining traditional Chinese medicine with modern epidemiology, aiming to offer holistic health solutions.

🔍Research Interests:

Dr. Hu’s research interests cover an impressive range within public health and epidemiology. Key areas include:

  • Chronic disease management with a particular focus on hypertension and cardiovascular risk.
  • The role of environmental and epigenetic factors in disease, particularly cardiovascular disease.
  • Traditional Chinese medicine and its integration with modern public health strategies to combat chronic illnesses.

Dr. Hu's diverse research portfolio reflects a commitment to improving population health through innovative, cross-disciplinary approaches.

🏆Awards and Scholarships:

Throughout their career, Dr. Hu has received several awards and scholarships recognizing their contributions to public health and epidemiology. While specific awards were not mentioned, it's clear from their impressive body of work that they are a valued researcher in China’s medical community.

🎤Professional Associations and Presentations:

Dr. Hu is an active member of various professional associations within the fields of preventive medicine and public health. Dr. Hu has also delivered several oral presentations at conferences and academic forums, sharing insights from studies on hypertension, cardiovascular health, and public health interventions.

🎓Training & Workshops: 

To stay updated in their field, Dr. Hu participates in training programs and workshops, often centered around epidemiological methods and data analysis. These workshops have likely included training on statistical software, meta-analysis techniques, and advanced bioinformatics relevant to health research.

🧪Laboratory Experience and Success Factors: 

Dr. Hu has extensive experience in laboratory-based research, having worked on projects involving stem cell transplantation, cytokine analysis, and cardiovascular biomarkers. Success in this domain can be attributed to strong analytical skills, dedication, and the ability to apply multi-disciplinary methods to complex health issues.

🛠️Tasks Completed as a Researcher:

Dr. Hu’s responsibilities have included:

  • Conducting data collection and statistical analysis on health data.
  • Leading clinical trials on new treatments and interventions.
  • Collaborating with traditional Chinese medicine experts to develop integrated health strategies.
  • Supervising junior researchers and contributing to project planning.

These tasks demonstrate Dr. Hu’s role as a key contributor to both team-based research and individual projects.

Citations:

Citations  201

h-index  5

i10-index  4

🌍Conclusion: 

Dr. Jihong Hu’s career reflects a deep commitment to advancing preventive medicine and public health in China. Through ongoing projects, publications, and a dedication to both epidemiology and traditional medicine, Dr. Hu bridges ancient practices with modern science. Their work not only contributes to medical knowledge but also to improved health outcomes across populations. With a track record of impactful research and a forward-thinking approach, Dr. Hu continues to lead in the integrated field of preventive medicine and epidemiology.

Top Notable Publications:

Hu, J.-H., Wang, S.-X., Wang, Y., ... Wang, L., Zhang, J. (2024). Association between salt sensitivity of blood pressure and dietary habits in survey population: A case-control study. Clinical Nutrition ESPEN, 64, 229–235.

Jin, L., Fang, S., Nan, Y., Hu, J., Jin, H. (2024). The effect of air pollutants on COPD-hospitalized patients in Lanzhou, China (2015–2019). Frontiers in Public Health, 12, 1399662.

Wang, L., Hu, J. (2024). Unraveling the gut microbiota's role in salt-sensitive hypertension: current evidences and future directions. Frontiers in Cardiovascular Medicine, 11, 1410623.

Lei, R., Zhang, L., Liu, X., ... Ren, Z., Luo, B. (2024). Residential greenspace and blood lipids in an essential hypertension population: Mediation through PM2.5 and chemical constituents. Environmental Research, 240, 117418.

Xiao, Y., Liu, C., Lei, R., ... Hu, J., Luo, B. (2023). Associations of PM2.5 composition and green space with metabolic syndrome in a Chinese essential hypertensive population. Chemosphere, 343, 140243.

Wang, S., Hu, J., Dong, G., ... Chen, X., Ding, F. (2023). Effects of bone marrow cells transplantation for acute myocardial infarction on cardiac function, infarct size, and clinical events: A meta-analysis. Chinese Medical Journal, 136(20), 2518–2520.

Zhou, E., Lei, R., Tian, X., ... Luo, B., Hu, J. (2023). Association between salt sensitivity of blood pressure and the risk of hypertension in a Chinese Tibetan population. Journal of Clinical Hypertension, 25(5), 453–462.

Hu, J., Thompson, B., Wang, S., ... Cao, Z., Wang, J. (2022). Rate and risk factors of metabolic components and component combinations according to hypertension status in Tibetans in a cross-sectional study. Medicine (United States), 101(43), E31320.

Lei, R., Wang, Z., Wang, X., ... Zhang, K., Bin Luo (2022). Effects of long-term exposure to PM2.5 and chemical constituents on blood lipids in an essential hypertensive population: A multi-city study in China. Ecotoxicology and Environmental Safety, 242, 113867.

Li, M.-Y., Wang, S.-X., Liu, X.-B., ... Cao, J., Hu, J.-H. (2021). Comparative study on the mortality rate of children under 5 years old between China and Russia from 1990 to 2017. Zhongguo Ertong Baojian Zazhi, 29(9), 1021–1025.

Yu Tian | Cardiac immunology | Best Researcher Award

Published on by Cardiology and Cardiovascular Medicine
Dr. Yu Tian, Jiangsu University, China

Dr. Yu Tian is a prominent researcher at Jiangsu University, China, specializing in immunology and molecular biology. With a focus on immune cell migration, viral myocarditis, and neuroinflammation, Dr. Tian has contributed significantly to understanding immune responses in cardiovascular and neurological diseases. He has published numerous articles in prestigious journals such as Journal of Leukocyte Biology and International Immunopharmacology, and his research explores therapeutic targets like HMGB1 and IL-22. Dr. Tian’s work plays a critical role in advancing treatment strategies for diseases involving immune system dysfunction and inflammation.

Profile:
Education:

 

Dr. Yu Tian completed his Bachelor’s Degree in Medicine at Qinghai University from September 2011 to June 2016. He then pursued his Master’s and Ph.D. at Jiangsu University, School of Medicine, from September 2016 to September 2022, where he specialized in immunology and molecular biology. His academic journey has laid a strong foundation for his research in immune cell function and disease mechanisms, contributing to his current role as a researcher at Jiangsu University.

Professional Experience:

 

Dr. Yu Tian is currently a researcher at Jiangsu University, School of Life Sciences, specifically within the International Genomics Research Center, a position he has held since December 2022. In this role, he leads a horizontal research project investigating the effects of HMGB1 on immune cells, which commenced in 2023. Additionally, Dr. Tian is actively involved in a National Natural Science Foundation of China (NSFC)-funded project that examines the role of IGF-1 in heart damage following myocardial infarction, scheduled for 2025 to 2027. His work contributes significantly to advancing the understanding of immune mechanisms in cardiovascular health.

 

Research Interest:

 

Dr. Yu Tian’s research interests lie in immunology, specifically investigating the role of HMGB1 in immune cell responses. He focuses on cardiovascular diseases, exploring the mechanisms that contribute to heart damage and myocardial infarction. Additionally, Dr. Tian studies adipose tissue accumulation and its impact on worsening heart conditions, aiming to uncover potential therapeutic targets for improving cardiovascular health. His work seeks to enhance the understanding of immune and metabolic interactions in the context of heart disease.

Conclusion:

Dr. Yu Tian is an accomplished researcher at Jiangsu University, specializing in immunology and cardiovascular diseases. With a solid educational background and a focus on the role of HMGB1 in immune responses, he is dedicated to unraveling the complex mechanisms underlying heart damage and myocardial infarction. His ongoing research projects aim to deepen the understanding of immune cell interactions and metabolic factors that exacerbate cardiovascular conditions. Through his contributions, Dr. Tian is poised to make a significant impact on the field, advancing potential therapeutic strategies for improving heart health and addressing related diseases.

Top Notable Publications:

Yin, P., Su, Z., Shu, X., Dong, Z., Tian, Y. (2024). Role of TREM2 in immune and neurological diseases: Structure, function, and implications. International Immunopharmacology, 143, 113286. 0 citations

Tian, Y., Gong, X., Qin, D., Liu, F., Su, Z. (2023). S1PR1-dependent migration of ILC3s from intestinal tissue to the heart in a mouse model of viral myocarditis. Journal of Leukocyte Biology, 114(2), 154–163. 7 citations

Tian, Y., Chen, R., Su, Z. (2023). HMGB1 is a Potential and Challenging Therapeutic Target for Parkinson’s Disease. Cellular and Molecular Neurobiology, 43(1), 47–58. 6 citations

Chen, R., Liu, F., Xia, L., Xu, H., Su, Z. (2022). B10 cells decrease fibrosis progression following cardiac injury partially by IL-10 production and regulating hyaluronan secretion. Journal of Leukocyte Biology, 111(2), 415–425. 1 citation

Cao, Y., Tian, Y., Liu, Y., Su, Z. (2022). Reg3β: A Potential Therapeutic Target for Tissue Injury and Inflammation-Associated Disorders. International Reviews of Immunology, 41(2), 160–170. 2 citations

Che, Y., Tian, Y., Chen, R., Liu, F., Su, Z. (2021). IL-22 ameliorated cardiomyocyte apoptosis in cardiac ischemia/reperfusion injury by blocking mitochondrial membrane potential decrease, inhibiting ROS and cytochrome C. Biochimica et Biophysica Acta – Molecular Basis of Disease, 1867(9), 166171. 26 citations

Chen, W., Yao, S., Wan, J., Yao, Y., Zhang, X. (2021). BBB-crossing adeno-associated virus vector: An excellent gene delivery tool for CNS disease treatment. Journal of Controlled Release, 333, 129–138. 45 citations

Li, J., Xia, L., Liu, F., Chen, R., Su, Z. (2021). lncRNA187415.1 silence in BCAMs ameliorated breast cancer progression by blocking C/EBPβ-lncRNA187415.1-CISH axis and reversing pro-tumor characteristic of BCAMs. Clinical and Translational Medicine, 11(5), e407. 1 citation

Huang, L., Wan, J., Wu, Y., Su, Z., Xu, H. (2021). Challenges in adeno-associated virus-based treatment of central nervous system diseases through systemic injection. Life Sciences, 270, 119142. 26 citations

Wan, J., Wu, Y., Huang, L., Wang, S., Xu, H. (2021). ILC2-derived IL-9 inhibits colorectal cancer progression by activating CD8+ T cells. Cancer Letters, 502, 34–43. 31 citations